MIRA Pharmaceuticals, Inc. Common Stock (MIRA) - Total Assets
Based on the latest financial reports, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) holds total assets worth $7.63 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
MIRA Pharmaceuticals, Inc. Common Stock - Total Assets Trend (2020–2024)
This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see market cap of MIRA Pharmaceuticals, Inc. Common Stock for the company's overall valuation and market capitalisation.
MIRA Pharmaceuticals, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
MIRA Pharmaceuticals, Inc. Common Stock's total assets of $7.63 Million consist of 98.8% current assets and 1.2% non-current assets. Review MIRA Pharmaceuticals, Inc. Common Stock (MIRA) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See MIRA Pharmaceuticals, Inc. Common Stock (MIRA) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MIRA Pharmaceuticals, Inc. Common Stock's current assets represent 98.8% of total assets in 2024, an increase from 15.6% in 2020.
- Cash Position: Cash and equivalents constituted 96.9% of total assets in 2024, up from 15.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
MIRA Pharmaceuticals, Inc. Common Stock Competitors by Total Assets
Key competitors of MIRA Pharmaceuticals, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $32.09 Billion |
MIRA Pharmaceuticals, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 90.53 | 6.11 | 4.16 |
| Quick Ratio | 90.53 | 6.11 | 4.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.51 Million | $3.54 Million | $1.69 Million |
MIRA Pharmaceuticals, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between MIRA Pharmaceuticals, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.38 |
| Latest Market Cap to Assets Ratio | 10.88 |
| Asset Growth Rate (YoY) | -40.7% |
| Total Assets | $2.92 Million |
| Market Capitalization | $31.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values MIRA Pharmaceuticals, Inc. Common Stock's assets at a significant premium (10.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: MIRA Pharmaceuticals, Inc. Common Stock's assets decreased by 40.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MIRA Pharmaceuticals, Inc. Common Stock (2020–2024)
The table below shows the annual total assets of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.92 Million | -40.74% |
| 2023-12-31 | $4.93 Million | +474.83% |
| 2022-12-31 | $858.07K | -74.43% |
| 2021-12-31 | $3.36 Million | +14897.83% |
| 2020-12-31 | $22.37K | -- |
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling tr… Read more